Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice-Reference-Cited by-同舟云学术

Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice

Published:2021-03-01 Issue:3 Volume:6 Page:267
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Vaduganathan Muthiah¹,Greene Stephen J.²,Zhang Shuaiqi²,Grau-Sepulveda Maria²,DeVore Adam D.²,Butler Javed³,Heidenreich Paul A.⁴,Huang Joanna C.⁵,Kittleson Michelle M.⁶,Joynt Maddox Karen E.⁷,McDermott James J.⁵,Owens Anjali Tiku⁸,Peterson Pamela N.⁹,Solomon Scott D.¹,Vardeny Orly¹⁰,Yancy Clyde W.¹¹¹²,Fonarow Gregg C.¹³¹⁴

Affiliation:

1. Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

2. Duke Clinical Research Institute and Division of Cardiology, Duke University School of Medicine, Durham, North Carolina

3. Department of Medicine, University of Mississippi Medical Center, Jackson

4. Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California

5. AstraZeneca, Wilmington, Delaware

6. Department of Cardiology, Smidt Heart Institute, Cedars-Sinai, Los Angeles, California

7. Department of Medicine, Cardiovascular Division, Washington University School of Medicine, St Louis, Missouri

8. Heart and Vascular Center, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia

9. Department of Medicine, Denver Health Medical Center, Denver, Colorado

10. Center for Care Delivery and Outcomes Research, Minneapolis Veterans Affairs Health Care System and University of Minnesota, Minneapolis

11. Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

12. Deputy Editor, JAMA Cardiology

13. Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, Los Angeles

14. Associate Editor for Health Care Quality and Guidelines, JAMA Cardiology

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2773092/jamacardiology_vaduganathan_2020_oi_200080_1614280612.00798.pdf

Reference35 articles.

1. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes.;Shah;J Am Coll Cardiol,2017

2. The average lifespan of patients discharged from hospital with heart failure.;Alter;J Gen Intern Med,2012

3. National burden of heart failure events in the United States, 2006 to 2014.;Jackson;Circ Heart Fail,2018

4. Dapagliflozin in patients with heart failure and reduced ejection fraction.;McMurray;N Engl J Med,2019

5. Cardiovascular and renal outcomes with empagliflozin in heart failure.;Packer;N Engl J Med,2020

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving Utilization of Guideline-Directed Medical Therapy for Heart Failure;The Journal for Nurse Practitioners;2024-09

2. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function;Journal of the American College of Cardiology;2024-06

3. Evaluation of Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitor Prescribing Patterns in Heart Failure Patients at Hospital Discharge;Journal of Pharmacy Practice;2024-05-27

4. Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea;American Journal of Cardiovascular Drugs;2024-02-27

5. Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems—A Literature Review;International Journal of Molecular Sciences;2024-02-06